

Martin Filipits

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8544457/publications.pdf>

Version: 2024-02-01

89
papers

5,676
citations

159585

30
h-index

76900

74
g-index

91
all docs

91
docs citations

91
times ranked

8108
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 355, 983-991.	27.0	1,611
2	A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. <i>Clinical Cancer Research</i> , 2011, 17, 6012-6020.	7.0	597
3	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485
4	EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. <i>Clinical Cancer Research</i> , 2009, 15, 4554-4560.	7.0	258
5	Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. <i>Journal of Clinical Oncology</i> , 2015, 33, 916-922.	1.6	189
6	The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1298-1305.	7.0	182
7	MicroRNA Expression and Clinical Outcomes in Patients Treated with Adjuvant Chemotherapy after Complete Resection of Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2010, 70, 8288-8298.	0.9	121
8	Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non-Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program. <i>Journal of Clinical Oncology</i> , 2007, 25, 2735-2740.	1.6	107
9	Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib. <i>Targeted Oncology</i> , 2019, 14, 75-83.	3.6	102
10	Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1161-1168.	1.6	97
11	MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 1206-1215.	7.0	89
12	Decentral gene expression analysis for ER+/Her2 ⁺ breast cancer: results of a proficiency testing program for the EndoPredict assay. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 251-259.	2.8	88
13	Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 1767-1774.	7.0	81
14	Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 149-157.	2.5	79
15	Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 850-861.	1.1	78
16	Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program. <i>Clinical Cancer Research</i> , 2007, 13, 3892-3898.	7.0	73
17	Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. <i>Journal of Oral Pathology and Medicine</i> , 2012, 41, 40-46.	2.7	69
18	Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. <i>BMC Cancer</i> , 2012, 12, 456.	2.6	66

#	ARTICLE	IF	CITATIONS
19	Mechanisms of cancer: multidrug resistance. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 229-234.	0.8	62
20	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	2.5	61
21	The potential of liquid biopsies. <i>Current Opinion in Oncology</i> , 2016, 28, 130-134.	2.4	59
22	Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2 ⁺ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. <i>Clinical Cancer Research</i> , 2019, 25, 3865-3872.	7.0	54
23	Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 821-830.	1.1	53
24	Expression of Cell Cycle Regulatory Proteins in Breast Carcinomas Before and After Preoperative Chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 97-103.	2.5	52
25	High p27 ^{Kip1} Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin. <i>Journal of Clinical Oncology</i> , 2003, 21, 3594-3600.	1.6	51
26	PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs. <i>Lung Cancer</i> , 2013, 80, 216-222.	2.0	40
27	Targeted Therapies in Lung Cancer. <i>Current Pharmaceutical Design</i> , 2009, 15, 188-206.	1.9	39
28	Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer. <i>Molecular Oncology</i> , 2014, 8, 555-564.	4.6	36
29	Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives. <i>Clinical Lung Cancer</i> , 2019, 20, 1-6.	2.6	36
30	EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR. <i>Targeted Oncology</i> , 2019, 14, 197-203.	3.6	33
31	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. <i>Neuro-Oncology</i> , 2017, 19, 1183-1194.	1.2	31
32	PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e957-e963.	2.6	31
33	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	7.0	29
34	The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. <i>European Journal of Cancer</i> , 2020, 134, 99-106.	2.8	29
35	Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 5888-5894.	7.0	26
36	IDO1+ Paneth cells promote immune escape of colorectal cancer. <i>Communications Biology</i> , 2020, 3, 252.	4.4	26

#	ARTICLE	IF	CITATIONS
37	EV11 promotes tumor growth via transcriptional repression of MS4A3. <i>Journal of Hematology and Oncology</i> , 2015, 8, 28.	17.0	25
38	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	5.9	25
39	Myeloid <i>STAT3</i> promotes formation of colitis-associated colorectal cancer in mice. <i>Oncolmmunology</i> , 2015, 4, e998529.	4.6	24
40	EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib. <i>Translational Lung Cancer Research</i> , 2020, 9, 239-245.	2.8	24
41	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSC 34). <i>European Journal of Cancer</i> , 2020, 132, 43-52.	2.8	24
42	Predictive markers in the adjuvant therapy of non-small cell lung cancer. <i>Lung Cancer</i> , 2011, 74, 355-363.	2.0	22
43	Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. <i>Pharmacoeconomics</i> , 2015, 33, 179-190.	3.3	22
44	From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000548.	4.5	22
45	Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4682-4687.	7.0	22
46	Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. <i>Modern Pathology</i> , 2014, 27, 906-915.	5.5	21
47	EV11 Inhibits Apoptosis Induced by Antileukemic Drugs via Upregulation of CDKN1A/p21/WAF in Human Myeloid Cells. <i>PLoS ONE</i> , 2013, 8, e56308.	2.5	20
48	New developments in the treatment of squamous cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 152-158.	2.4	20
49	<i>HCRP1</i> expression status is a significant prognostic marker in oral and oropharyngeal cancer. <i>Oral Diseases</i> , 2013, 19, 206-211.	3.0	19
50	LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 66-73.e6.	2.6	19
51	Cetuximab in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2012, 1, 54-60.	2.8	18
52	Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 68-77.	2.4	17
53	Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study. <i>Translational Lung Cancer Research</i> , 2021, 10, 1594-1607.	2.8	17
54	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	7.0	17

#	ARTICLE	IF	CITATIONS
55	Integrating Epidermal Growth Factor Receptor-Targeted Therapies into Platinum-Based Chemotherapy Regimens for Newly Diagnosed Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, S109-S115.	2.6	15
56	Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study. <i>Clinical Cancer Research</i> , 2018, 24, 3079-3086.	7.0	15
57	Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7828-7834.	7.0	13
58	Late Recurrences in Early Breast Cancer: For Whom and How Long Is Endocrine Therapy Beneficial?. <i>Breast Care</i> , 2014, 9, 97-97.	1.4	12
59	ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. <i>ESMO Open</i> , 2021, 6, 100228.	4.5	11
60	Prognostic and predictive effects of KRAS mutation subtype in completely resected non-small cell lung cancer (NSCLC): A LACE-bio study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7007-7007.	1.6	9
61	PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. <i>Molecular Imaging and Biology</i> , 2019, 21, 991-1002.	2.6	8
62	The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib. <i>Targeted Oncology</i> , 2021, 16, 77-84.	3.6	8
63	Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199307.	1.3	8
64	D3-03: IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC. <i>Journal of Thoracic Oncology</i> , 2007, 2, S397-S398.	1.1	7
65	Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients. <i>Biomolecules</i> , 2021, 11, 618.	4.0	7
66	Low protein expression of MET in ER-positive and HER2-positive breast cancer. <i>Anticancer Research</i> , 2014, 34, 1227-31.	1.1	6
67	Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?. <i>OncoTargets and Therapy</i> , 2015, 8, 1843.	2.0	5
68	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 545-555.	2.8	5
69	Lung Cancer in Austria. <i>Journal of Thoracic Oncology</i> , 2021, 16, 725-733.	1.1	5
70	Predicting local recurrence using PAM50 in postmenopausal endocrine responsive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1008-1008.	1.6	5
71	Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?. <i>Translational Lung Cancer Research</i> , 2015, 4, 797-800.	2.8	5
72	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	7.0	4

#	ARTICLE	IF	CITATIONS
73	PD1 and PD-L1 expression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2011-2011.	1.6	4
74	Hot Spot TERT Promoter Mutations Are Rare in Sporadic Pancreatic Neuroendocrine Neoplasms and Associated with Telomere Length and Epigenetic Expression Patterns. Cancers, 2020, 12, 1625.	3.7	3
75	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. British Journal of Cancer, 2021, 124, 1795-1802.	6.4	3
76	Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA. Experimental and Molecular Pathology, 2021, 123, 104685.	2.1	3
77	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	1.6	3
78	Retrospective analysis of the prevalence of specialised palliative care services for patients with metastatic breast cancer. ESMO Open, 2020, 5, e000905.	4.5	2
79	EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.. Journal of Clinical Oncology, 2016, 34, e20572-e20572.	1.6	2
80	Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. Memo - Magazine of European Medical Oncology, 2008, 1, 57-60.	0.5	1
81	The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptorâ€“Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8. Clinical Cancer Research, 2021, 27, 5931-5938.	7.0	1
82	Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines.. Journal of Clinical Oncology, 2012, 30, 542-542.	1.6	1
83	Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. Anticancer Research, 2020, 40, 6229-6236.	1.1	1
84	Breast cancer: is there a need for biopsy of metastases?. Memo - Magazine of European Medical Oncology, 2012, 5, 125-128.	0.5	0
85	Biomarkersâ€™hope and hype. Memo - Magazine of European Medical Oncology, 2015, 8, 204-204.	0.5	0
86	A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. Memo - Magazine of European Medical Oncology, 2015, 8, 52-56.	0.5	0
87	PIK3CA mutational status and correlation with tumor glycolysis imaged with [18F]FDG PET/CT in early primary ER+ / HER2- breast cancer patients: A feasibility study.. Journal of Clinical Oncology, 2016, 34, e12050-e12050.	1.6	0
88	Abstract PR005: <i>TP53</i> field defects in uterine fluid are associated with ovarian cancer risk. Cancer Research, 2022, 82, PR005-PR005.	0.9	0
89	Abstract A008: <i>TP53</i> field defects in uterine fluid are associated with ovarian cancer risk. Cancer Research, 2022, 82, A008-A008.	0.9	0